Cassava Sciences: Analysts See 300% UpsideDespite Controversies
Oct 30, 2024
Alzheimer's Invest Information
Athira Pharma Announces Key Milestones with Upcoming Presentation of LIFT-AD Clinical Trial Results for Alzheimer's Treatment
Aug 2, 2024
FDA Approves Lilly's Kisunla™ for Early Symptomatic Alzheimer's
Jul 3, 2024
Eisai Submits LEQEMBI® (lecanemab-irmb) Biologics License Update to FDA for Early Alzheimer's Treatment – Biogen Stocks in Focus
Jun 10, 2024
Athira Pharma Unveils Encouraging Clinical and Preclinical Results for Fosgonimeton at the AD/PD™ 2024 Conference
Mar 9, 2024
Biogen Showcases Fresh Insights on Alzheimer's Disease at AD/PD™ 2024 Conference
Mar 5, 2024
Athira Pharma Showcases Neuroprotective Properties of Fosgonimeton in Alzheimer's Disease Models
Nov 16, 2023
Athira Pharma Demonstrates Promising Neuroprotective Abilities of Fosgonimeton in Alzheimer's Disease Models
Nov 15, 2023